Table 1

Patient characteristics

Patient	Sex	Age (years)	Disease duration (years)	UPDRS		H&Y	S&E		L-dopa dose (mg/day)	Dopamin agonist
Patient	Sex	Age (years)	Disease duration (years)	On	Off	H&Y	On	Off	L-dopa dose (mg/day)	Dopamin agonist
*Patients dropped out after training.
F, female; H&Y, Hoehn and Yahr stage; M, male; S&E, Schwab and England score; UPDRS, Unified Parkinson’s Disease Rating Scale, version 3.0.
1	F	74	7	51	51	3	80%	80	250	Dihydroergocriptine
2	F	73	15	79	86	4	70%	50	600	Ropinirole
3	F	60	3	37	42	2.5	90%	80	250	Cabergoline
4	F	70	6	77	91	4	70%	50	350	Pergolide
5	F	78	12	24	27	2.5	80%	70	400	Pergolide
6	F	65	21	20	38	3	90%	60	1025	Pramipexole
7	M	65	7	69	81	4	60%	30	550	Pramipexole
8	F	78	3	50	50	2.5	80%	80	0	Pramipexole
9	F	81	2	16	16	2.5	90%	90	0	Dihydroergocriptine
10	M	78	6	60	67	3	70%	50	600	Pramipexole
11	F	77	8	37	48	3	80%	60	350	Dihydroergocriptine
12*	M	80	9	37	37	2.5	80%	80	250	Lisuride
13*	M	70	5	44	44	2.5	80%	80	500	Cabergoline
14*	F	72	3	34	40	2.5	80%	80	400